If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Akira Hirasawa is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 13 Similar Profiles
Endometrial Neoplasms Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Hereditary Nonpolyposis Colorectal Neoplasms Medicine & Life Sciences
Ovarian Neoplasms Medicine & Life Sciences
DNA Mismatch Repair Medicine & Life Sciences
Genes Medicine & Life Sciences
Microsatellite Instability Medicine & Life Sciences
Germ-Line Mutation Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1999 2019

1 Citation (Scopus)

Guidelines for office gynecology in Japan: Japan Society of Obstetrics and Gynecology (JSOG) and Japan Association of Obstetricians and Gynecologists (JAOG) 2017 edition

Kawaguchi, R., Matsumoto, K., Akira, S., Ishitani, K., Iwasaku, K., Ueda, Y., Okagaki, R., Okano, H., Oki, T., Koga, K., Kido, M., Kurabayashi, T., Kuribayashi, Y., Sato, Y., Shiina, K., Takai, Y., Tanimura, S., Chaki, O., Terauchi, M., Todo, Y. & 14 others, Noguchi, Y., Nose-Ogura, S., Baba, T., Hirasawa, A., Fujii, T., Fujii, T., Maruyama, T., Miyagi, E., Yanagida, K., Yoshino, O., Iwashita, M., Maeda, T., Minegishi, T. & Kobayashi, H., Apr 1 2019, In : Journal of Obstetrics and Gynaecology Research. 45, 4, p. 766-786 21 p.

Research output: Contribution to journalArticle

Gynecology
Obstetrics
Japan
Guidelines
Endocrinology

Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition

Mishima, S., Taniguchi, H., Akagi, K., Baba, E., Fujiwara, Y., Hirasawa, A., Ikeda, M., Maeda, O., Muro, K., Nishihara, H., Nishiyama, H., Takano, T., Tsuchihara, K., Yatabe, Y., Kodera, Y. & Yoshino, T., Jan 1 2019, In : International Journal of Clinical Oncology.

Research output: Contribution to journalArticle

Open Access
DNA Repair-Deficiency Disorders
DNA Mismatch Repair
Medical Oncology
Immunotherapy
Japan
4 Citations (Scopus)

ADAM9 is over-expressed in human ovarian clear cell carcinomas and suppresses cisplatin-induced cell death

Ueno, M., Shiomi, T., Mochizuki, S., Chijiiwa, M., Shimoda, M., Kanai, Y., Kataoka, F., Hirasawa, A., Susumu, N., Aoki, D. & Okada, Y., Feb 1 2018, In : Cancer Science. 109, 2, p. 471-482 12 p.

Research output: Contribution to journalArticle

Cisplatin
Cell Death
Carcinoma
Disintegrins
Metalloproteases

GSTP1 rs1695 is associated with both hematological toxicity and prognosis of ovarian cancer treated with paclitaxel plus carboplatin combination chemotherapy: A comprehensive analysis using targeted resequencing of 100 pharmacogenes

Yoshihama, T., Fukunaga, K., Hirasawa, A., Nomura, H., Akahane, T., Kataoka, F., Yamagami, W., Aoki, D. & Mushiroda, T., Jul 1 2018, In : Oncotarget. 9, 51, p. 29789-29800 12 p.

Research output: Contribution to journalArticle

Carboplatin
Paclitaxel
Combination Drug Therapy
Ovarian Neoplasms
Fallopian Tube Neoplasms
2 Citations (Scopus)

Is repeated high-dose medroxyprogesterone acetate (Mpa) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?

Yamagami, W., Susumu, N., Makabe, T., Sakai, K., Nomura, H., Kataoka, F., Hirasawa, A., Banno, K. & Aoki, D., Mar 1 2018, In : Journal of Gynecologic Oncology. 29, 2, e21.

Research output: Contribution to journalArticle

Endometrial Hyperplasia
Medroxyprogesterone Acetate
Endometrial Neoplasms
Fertility
Recurrence